SCHEMBL792945

SCHEMBL792945

COCN1CCN(c2cc(C)nc(C)n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORD Q00796 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.42
USP2 O75604 1/20 0.42
CRHBP P24387 2/20 0.41
CRHR2 Q13324 2/20 0.41
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
GFER P55789 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EHMT2 Q96KQ7 1/20 0.38
POLB P06746 1/20 0.37
CASP1 P29466 1/20 0.37
CASP4 P49662 1/20 0.37
CASP5 P51878 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22080093 0.82 SORD (0.54) SORDSMN1; SMN2CRHBPCRHR2KMT2A
SCHEMBL17194886 0.79 SORD (0.51) SORDSMN1; SMN2CRHBPCRHR2KMT2A
SCHEMBL11981518 0.78 SORD (0.57) SORDSMN1; SMN2KMT2AKDM4ELMNA
SCHEMBL14461289 0.78 SORD (0.50) SORDSMN1; SMN2CRHBPCRHR2KMT2A
SCHEMBL22275729 0.76 HRH4 (0.59) SORDSMN1; SMN2CRHBPCRHR2KMT2A
SCHEMBL792754 0.76 SORD (0.45) SORDSMN1; SMN2USP2CRHBPCRHR2
SCHEMBL14872339 0.76 CRHBP (0.59) SORDSMN1; SMN2USP2CRHBPCRHR2
SCHEMBL5790244 0.76 SMN1; SMN2 (0.65) SORDSMN1; SMN2USP2CRHBPCRHR2
SCHEMBL5791348 0.74 SMN1; SMN2 (0.68) SORDSMN1; SMN2USP2CRHBPCRHR2
SCHEMBL27920493 0.73 SORD (0.50) SORDSMN1; SMN2USP2CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9084828-B2 Oligomer-protein tyrosine kinase inhibitor conjugates NEKTAR THERAPEUTICS (US) 2015-07-21 US disclosed
US-20140329828-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2014-11-06 US disclosed
US-8816077-B2 Oligomer-protein tyrosine kinase inhibitor conjugates NEKTAR THERAPEUTICS (US) 2014-08-26 US disclosed
US-20120071492-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329828-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates PTK2B, ERBB2, FRK SORD 3868/4885SMN1; SMN2 3622/4885USP2 1491/4885
US-20120071492-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates PTK2B, ERBB2, FRK SORD 3906/4885SMN1; SMN2 3616/4885USP2 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.